Literature DB >> 22226336

Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas.

S Caillard1, F X Lamy, C Quelen, J Dantal, Y Lebranchu, P Lang, M Velten, B Moulin.   

Abstract

A registry of posttransplant lymphoproliferative disorders (PTLD) was set up for the entire population of adult kidney transplant recipients in France. Cases of PTLD were prospectively enrolled between January 1, 1998, and December 31, 2007. Ten-year cumulative incidence was analyzed in patients transplanted after January 1, 1989. PTLD risk factors were analyzed in patients transplanted after January 1, 1998 by Cox analysis. Cumulative incidence was 1% after 5 years, 2.1% after 10 years. Multivariate analysis showed that PTLD was significantly associated with: older age of the recipient 47-60 years and >60 years (vs. 33-46 years, adjusted hazard ratio (AHR) = 1.87, CI = 1.22-2.86 and AHR = 2.80, CI = 1.73-4.55, respectively, p < 0.0001), simultaneous kidney-pancreas transplantation (AHR = 2.52, CI = 1.27-5.01 p = 0.008), year of transplant 1998-1999 and 2000-2001 (vs. 2006-2007, AHR = 3.36, CI = 1.64-6.87 and AHR = 3.08, CI = 1.55-6.15, respectively, p = 0.003), EBV mismatch (HR = 5.31, CI = 3.36-8.39, p < 0.001), 5 or 6 HLA mismatches (vs. 0-4, AHR = 1.54, CI = 1.12-2.12, p = 0.008), and induction therapy (AHR = 1.42, CI = 1-2.02, p = 0.05). Analyses of subgroups of PTLD provided new information about PTLD risk factors for early, late, EBV positive and negative, polymorphic, monomorphic, graft and cerebral lymphomas. This nationwide study highlights the increased risk of PTLD as long as 10 years after transplantation and the role of cofactors in modifying PTLD risk, particularly in specific PTLD subgroups. © copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2012        PMID: 22226336     DOI: 10.1111/j.1600-6143.2011.03896.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  38 in total

1.  Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.

Authors:  Aaron S Rosenberg; Andreas K Klein; Robin Ruthazer; Andrew M Evens
Journal:  Am J Hematol       Date:  2016-04-26       Impact factor: 10.047

Review 2.  Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches.

Authors:  Fedaey Abbas; Mohsen El Kossi; Ihab Sakr Shaheen; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2020-02-28

3.  Impact of the posttransplant lymphoproliferative disorder subtype on survival.

Authors:  Jean L Koff; Jing-Xia Li; Xinyan Zhang; Jeffrey M Switchenko; Christopher R Flowers; Edmund K Waller
Journal:  Cancer       Date:  2018-03-26       Impact factor: 6.860

4.  Incidence, risk factors and outcomes of malignancies after kidney transplantation in Singapore: a 12-year experience.

Authors:  Su Hooi Teo; Kian-Guan Lee; Gek Hsiang Lim; Si Xuan Koo; Maria Erika Ramirez; Khuan Yew Chow; Terence Kee
Journal:  Singapore Med J       Date:  2018-10-10       Impact factor: 1.858

Review 5.  Transplantation of the pancreas.

Authors:  Ugo Boggi; Fabio Vistoli; Francesca Maria Egidi; Piero Marchetti; Nelide De Lio; Vittorio Perrone; Fabio Caniglia; Stefano Signori; Massimiliano Barsotti; Matteo Bernini; Margherita Occhipinti; Daniele Focosi; Gabriella Amorese
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

6.  Epidemiology of post-transplant malignancy in Asian renal transplant recipients: a population-based study.

Authors:  F Y Hsiao; W W Y Hsu
Journal:  Int Urol Nephrol       Date:  2013-09-06       Impact factor: 2.370

7.  A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders.

Authors:  Sophie Caillard; Etienne Cellot; Jacques Dantal; Olivier Thaunat; François Provot; Bénédicte Janbon; Matthias Buchler; Dany Anglicheau; Pierre Merville; Philippe Lang; Luc Frimat; Charlotte Colosio; Eric Alamartine; Nassim Kamar; Anne Elisabeth Heng; Antoine Durrbach; Valérie Moal; Joseph Rivalan; Isabelle Etienne; Marie Noelle Peraldi; Anne Moreau; Bruno Moulin
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-17       Impact factor: 8.237

8.  Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders.

Authors:  Aaron S Rosenberg; Robin Ruthazer; Jessica K Paulus; David M Kent; Andrew M Evens; Andreas K Klein
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-09-17

9.  Post cardiac transplantation T-cell lymphoproliferative disorder presenting as a solitary lung nodule.

Authors:  Barina Aqil; Bhuvaneswari Krishnan; Choladda V Curry; M Tarek Elghetany; Reka Szigeti
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

Review 10.  Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders.

Authors:  Grace Y Lam; Brendan P Halloran; Anthea C Peters; Richard N Fedorak
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.